Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter to Sell $525M in Notes to Support R&D, Pay Off Debt

NEW YORK (GenomeWeb News) — Beckman Coulter today said it plans to issue $525 million worth of convertible senior notes to help it pay off existing debt and pay for research and development.
 
The company also said it may buy back $100 million of its common stock to help that end.
 
Roughly $245 million of the debt proceeds will go toward its 7.45-percent senior notes due 2008, and $185 million will repay a bridge facility connected to its acquisition of Lumigen. The remainder of the funds will be used to reduce the company’s revolving credit facility.  
 
BC said the notes, due 2036, may be converted into cash up to the principle, or into shares depending on the conversion value.
 
BC said the other terms of the sale, including interest rate and conversion price, will be determined by the company and the notes’ buyers. The company also plans to grant initial buyers an option for as much as $75 million aggregate principal in other notes for over-allotments.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.